Althea Technologies, Inc. has entered a manufacturing supply agreement with Quintessence Biosciences to produce the firm’s first drug candidate, QBI-139. The drug is effective in cancer models against a broad range of solid tumors. Quintessence plans to file an IND with the FDA for QBI-139 in 1Q2008. Althea will provide protein production, purification, and aseptic filling services to produce the clinical trial materials.     “Althea is an outstanding company with significant expe...